| REFERENCIAS
(Tiroidectomia Total) |
1. Cady B. Our AMES
is true: how an old concept still hits the mark—or,
risk group assignment points the arrow to rational therapy
selection in differentiated. thyroid cancer. Am J Surg.
1997;174:462– 8.
2. Shaha AR, Loree TR, Shah JP. 1995 Prognostic
factors and risk group analysis in follicular carcinoma
of the thyroid. Surgery. 1995;118:1131–8.
3. Benninger MS, Guillen
JB, Altman JS. Changing etiology of vocal fold immobility.
Laryngoscope 1998;108;1346-50
4. Havas T, Lowinger D, Priestley J. Unilateral
vocal fold paralysis: causes, options and outcomes. Austr
N Z J Surg 1999;69:509-13
5. Fewins J, Simpson B, Miller FR. Complications
of thyroid and parathyroid surgery. Otolaryngologic Clinics
of North America 2003;36
6. Udelsman R, Lakatos E, Ladenson P. Optimal
surgery for papillary thyroid carcinoma. World J Surg
1996;20:88-93
7. Koyunku
A, Dokmetas HS, Turan M, Aydin C,Karayadi K, Budak E,
et al. Comparison of different thyroidectomy techniques
for benign thyroid disease. Endocrine Journal 2003;50:723-7
8. Rosato L, Avenia
N, Bernante P, De Palma M, Gulino G, Nasi PG, Pelizzo
MR, Pezzullo Complications of thyroid surgery: analysis
of a multicentric study on 14,934 patients operated on
in Italy over 5 years. World J Surg. 2004;28:271
9. Filho JG, Kowalski
LP. Postoperative complications of thyroidectomy for differentiated
thyroid carcinoma. Am J Otolaryngol. 2004;25:225-30.
10. Kupferman ME,
Mandel SJ, DiDonato L, Wolf P, Weber RS. Safety of completion
thyroidectomy following unilateral lobectomy for well-differentiated
thyroid cancer. Laryngoscope. 2002;112:1209-12.
11. Bhattacharyya N,
Fried MP. Assessment of the morbidity and complications
of total thyroidectomy. Arch Otolaryngol Head Neck Surg.
2002;128:389-92.
12.
Gough IR, Wilkinson D. Total thyroidectomy for
management of thyroid disease. World J Surg 2000;24:962-5
13. Clark OH. Total
thyroidectomy: the treatment of choice for patients with
differentiated thyroid cancer. An Surg 1982;196:361-70
14. Rodríguez
CS, Labastida AS, Olano NO, Muñoz CML. Morbilidad
debida a tiroidectomía por cáncer. Cir Gen
1996;18:92-97
15.
Hurtado-Lopez LM, Pulido-Cejudo A, Basurto-Kuba E. Puntos
clave para una adecuada y segura identificación
del nervio laringeo recurrente durante la tiroidectomía.
Aplicación en 100 tiroidectomías. Cir Gen
1998;20:95-98
16. Hurtado-López
LM, Pulido-cejudo A, Zaldivar-Ramirez FR, Basurto-Kuba
E. A propósito de la localización del nervio
laríngeo recurrente y las glándulas paratiroides
inferior en la cirugía de tiroides. Como lo hago
yo. Cir Gen 2000;22(3):283-286.
17.
Pulido Cejudo A, Hurtado-López LM, Basurto
Kuba E, Cárdenas del Olmo A, Muñoz Solís
O, Zaldívar Ramírez FR, Gómez Arciniega
M, Rangel Cruz ESH. Sistematización de la técnica
de tiroidectomía y su impacto en la morbilidad
Cir Gen. 2004;26:286-9
18.
Hurtado-López LM, Zaldivar-Ramirez FR, Basurto-Kuba
E, Pulido-cejudo A, Muñoz-Solis O, Cardenas-Del
Olmo A. La morbilidad no limita la extensión quirurgica
del cancer diferenciado de tiroides. Cir Gen 2003;25 (supl
1):s9-s10
19. Pasieka
JL, Rotstein LE. Consensus conference on well-differentiated
thyroid cancer: a summary. Can J Surg. 1993;36:298-301
20. Cernea CR,
Ferraz AR, Nishio S, Dutra A, Hojaji F, et al. Surgical
anatomy of the external branch of the superior laryngeal
nerve. Head & Neck 1992;14:380-383.
21.
Hurtado López LM, Zaldívar RF.
2002 Risk of injury to the external branch of the superior
laryngeal nerve in thyroidectomy. Laryngoscope 112:626-629.
22. Cernea CR,
Ferraz AR, Furlani J, Monteiro S, Nishio S, et al. 1992
Identification of the external branch of the superior
laryngeal nerve during thyroidectomy. Am J Surg 164:634-639.
23. Hurtado López
LM, Pacheco-Alvarez M I, Montes-Castillo M D L, Zaldivar-Ramirez
F-R. Importance of the intraoperative identification of
the external branch of the superior laryngeal nerve during
thyroidectomy. electromyographic evaluation. Thyroid (en
prensa)
24.
Madrid Franco JR, Lozano López I. Enfermedad quirúrgica
no traumática del cuello ¿estoy preparado
para enfrentarla? Cir Gen 2004;26:155-7
25.
Sosa, JA, et al. The Importance of Surgeon Experience
for Clinical and Economic Outcomes From Thyroidectomy:
Annals of Surgery; 1998, 228:320-30
26.
Baucourt F, Asselain B, Savie JC. Multifactorial
study of prognostic factors in diffentiated thyroid carcinoma
and a re-evaluation of the importance of age. Br J Surg
1986;73:274-77
27. McConahey
WM, Hay ID, Woolner LB, Van Heerden JA, Taylor WF. Papillary
thyroid cancer treated at the Mayo clinic, 1946 through
1970: inicial manifestations athologic findings, therpy
and outcome. Mayo Clin Proc 1986;61:978-96.
28. Avenia N, Ragusa
M, Monacelli M, Calzolari F, Daddi N, Di Carlo L, Semeraro
A, Puma F. Locally advanced thyroid cancer: therapeutic
options. Chir Ital. 2004;56:501-8.
29.
Marchesi M, Biffoni M, Biancari F, Berni A, Campana FP.
Predictors of outcome for patients with differentiated
and aggressive thyroid carcinoma. Eur J Surg Suppl. 2003;588:46-50
30. Kitamura Y,
Shimizu K, Nagahama M, et al. Immediate causes of death
in thyroid carcinoma: clinicopathological analysis of
161 fatal cases. J Clin Endocrinol Metab. 1999;84:4043–
4049.
31. Mazzaferri
EL, Young RL, Oertel JE, Kemmerer WT, Page CP. Papillary
thyroid carcinoma: the impact of therapy in 576 patients.
Medicine (Baltimore). 1977;56:171-96.
32.
Byar DP, Green SB, Dor P. A prognostic index
for thyroid carcinoma: a study of the EORTC thyroid cancer
cooperative group. Eur J cancer 1979;15:1033-41
33. Simpson WJ, McKinney
S. Canadian survey of thyroid cancer. Can Med Assoc J
1985;132:925-31
34.
Simpson WJ, McKinney S, Carruthers JS, Gospodarowics MK,
Papillary and follicular thyroid cancer. Prognostic factors
in 1578 patients. Am J Med 1987;83:479-88
35.
Hay ID, Grant CS, Taylor WF. Ipsilateral lobectomy
versus bilateral lobar resection in papillary thyroid
carcinoma: A retrospective analysis of surgical outcome
using a novel prognostic scoring system. Surgery 1987;102:1088-95
36. Cady B, Rossi
R. An expanded view of risk group definition in difefereniated
thyroid carcinoma. Surgery 1988; 104:947-53
37.
Hay ID, Bergstralh EJ, Goellner JR. Predicting
outcome in papillary thyroid carcinoma: development of
a reliable prognostic scoring system is a cohort of 1779
paients surgically treated at one institution during 1940
through 1989. Surgery 1993;114:1050-58
38.
DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural
history, treatment and course of papillary carcinoma J
Clin Endocrinol Metab 1990;71:414-24
39.
Shaha AR, Loree TR, Shah JP, Prognostic factors
and risk group analysis in follicular carcinoma ot the
thyroid. Surgery 1995;118:1131-38
40.
Sherman SI, Brierley JD, Sperling M. Prospective multicenter
study of thyroid carcinoma treatment. Initial analysis
of staging and outcome. National Thyroid Cancer Treatment
Cooperative study registry group. Cancer 1998;83:1012-21
41. Mazzaferri
EL.1999 NCCN thyroid carcinoma practice guidelines. Oncology
13(11A, NCCN proceedings):391-442
42.
Kitamura Y, Shimizu K, Nagahama M, Sugino K, Ozaki O,
Mimura T, Ito K, Ito K, Tanaka S. Immediate causes of
death in thyroid carcinoma: clinicopathological analysis
of 161 fatal cases. J Clin Endocrinol Metab. 1999;84:4043-9.
43. Rodriguez Cuevas
SA, Labastida AS, Rodríguez ME, Reyas CJM. Papillary
carcinoma in Mexico: análisis of 409 cases. Head
Neck 1993;15:537-45
44.
Herrera MF, Lopez-Graniel CM, Saldaña
J, Gamboa-Dominguez A, Richaud-Patin Y, VargasVorackova
F, et al. Papillary thyroid carcinoma in Mexican patients:
clinical aspects and prognostica factors World J Surg
1996;20:94-100
45. Mazzaferri
EL , Massoll N. Management of papillary and follicular
(differentiated) thyroid cancer: new paradigms using recombinant
human thyrotropin. Endocrine-Related cancer 2002;9:227
46. Scheumann GF,
Gimm O, Wegener G, Hundeshagen H, Dralle H. Prognostic
significance and surgical management of locoregional lymph
node metastases in papillary thyroid cancer. World J surg
1994;18:559
47. Beasley
NJ, Lee J, Eski S, Walfish P, Witterck I, Freeman JL.
Impact of nodal metastasis on prognosis in patients with
well-differentiated thyroid cancer. Arch Oyolaryngol Head
Neck Surg 2002;128:825
48.
Clark OH. Total thyroidectomy: the treatment
of choice for patients with differentiated thyroid cancer.
Ann Surg 1982;196:361-70
49.
Schlumberger M, Arcangioli O, Piekarski JD, Tubiana
M, Parmentier C. Detection and treatment of lung metastases
of differentiated thyroid carcinoma in patients with normal
chest X-rays. J Nucl Med. 1988;29:1790-4.
50.
Dackiw AP, Zeiger M. Extent of surgery for differentiated
thyroid cancer Surg Clin North Am 2004;84: 817-32
51. McConahey WM,
Hay ID, Woolner LB, van Heerden JA, Taylor WF. Papillary
thyroid cancer treated at the Mayo Clinic, 1946 through
1970: initial manifestations, pathologic findings, therapy,
and outcome. Mayo Clin Proc. 1986;61:978-96.
52. Massin JP, Savoie
JC, Garnier H, Guiraudon G, Leger FA, Bacourt F. Pulmonary
metastases in differentiated thyroid carcinoma. Study
of 58 cases with implications for the primary tumor treatment.Cancer.
1984;53:982-92.
53.
Mishra A, Mishra SK, Agarwal A, Das BK, Agarwal
G, Gambhir S. Metastatic differentiated thyroid carcinoma:
clinicopathological profile and outcome in an iodine deficient
area. World J Surg. 2002;26:153-7.
54.
Pacini F, Cetani F, Miccoli P, Mancusi F, Ceccarelli
C, Lippi F, Martino E, Pinchera A. Outcome of 309 patients
with metastatic differentiated thyroid carcinoma treated
with radioiodine. World J Surg. 1994;18:600-4.
55. Zohar Y, Strauss
M. Occult distant metastases of well-differentiated thyroid
carcinoma. Head Neck.1994;16:438-42.
56.
Mazzaferri EL, Kloos RT. Current approaches to
primary therapy for papillary and follicular thyroid cancer.
J Clin Endocrinol Metab 2001;86:1447-63
57.
Hay ID, Grant CS, Bergstralh EJ, Thompson GB, van Heerden
JA, Goellner JR. Unilateral total lobectomy: is it sufficient
surgical treatment for patients with AMES low-risk papillary
thyroid carcinoma? Surgery 1998;124:958-64.
58.
DeGroot LJ, Kaplan EL, Straus FH, Shukla MS.
Does the method of management of papillary thyroid carcinoma
make a difference in outcome? World J Surg 1994;18:123-30.
59. Cushing SL,
Palme CE, Audet N, Eski S, Walfish PG, Freeman JL. Prognostic
Factors in Well-Differentiated Thyroid Carcinoma. Laryngoscope.
2004;114:2110-15.
60.
Orsenigo E, Beretta E, Fiacco E, Scaltrini F,
Veronesi P, Invernizzi L, Gini P, Fiorina P, Di Carlo
V.Management of papillary microcarcinoma of the thyroid
gland. Eur J Surg Oncol. 2004 Dec;30(10):1104-6. Orsenigo
E, Beretta E, Fiacco E, Scaltrini F, Veronesi P, Invernizzi
L, Gini P, Fiorina P, Di Carlo V.Management of papillary
microcarcinoma of the thyroid gland. Eur J Surg Oncol.
2004;30:1104-6.
61.
Kim S, Wei JP, Braveman JM, Brams DM. Predicting
outcome and directing therapy for papillary thyroid carcinoma.
Arch Surg. 2004;139:390-4.
62.
Ashok R. Shaha, Implications of Prognostic Factors and
Risk Groups in the Management of Differentiated Thyroid
Cancer Laryngoscope,2004;114:393–402.
63.
Aldred MA, Huang Y, Liyanarachchi S, Pellegata
NS, Gimm O, Jhiang S, et al. Papillary and follicular
thyroid carcinomas show distinctly different microarray
expression profiles and can be distinguished by a minimum
of five genes. J Clin Oncol. 2004;22:3531-9.
64. Pellegriti G, Scollo
C, Lumera G, Regalbuto C, Vigneri R, Belfiore A Clinical
behavior and outcome of papillary thyroid cancers smaller
than 1.5 cm in diameter: study of 299 cases. J Clin Endocrinol
Metab. 2004;89:3713-20
65.
Spitzweg C, Morris JC. Gene therapy for thyroid cancer:
Current status and future prospects. Thyroid 2004;14:424-34 |
Índice